HFpEF and 2-year Mortality of COPD Patients

Recruiting

• Conditions: Heart Failure; Chronic Obstructive Pulmonary Disease
• Interventions: Diagnostic Test: Cardiac function assessment

• Registration Number: NCT04277429
• Lead Sponsor: University Hospital Olomouc

Brief Summary

This study was designed to assess potential relationship between heart failure with preserved ejection fraction and 2- year mortality of patients with chronic obstructive pulmonary disease

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-02-17
• Study First Submitted QC: 2020-02-17
• Study First Posted: 2020-02-20
• Study Start: 2020-07-01
• Status Verified: 2022-11
• Last Update Submitted: 2022-11-01
• Last Update Posted: 2022-11-02
• Primary Completion: 2025-04-01
• Study Completion: 2025-04-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

Exacerbation of chronic obstructive pulmonary disease requiring hospitalization

Age 40 - 80 years

Performance status 0-1 according to Eastern Cooperative Oncology Group (ECOG)

Long acting beta agonist (LABA)/ long acting antimuscarinic (LAMA) bronchodilator treatment

Exclusion Criteria

Presence of major heart valve dysfunction

Documented noncompliance with treatment

Presence of active malignancy

Body mass index > 40

Interstitial lung disease

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Normal cardiac function	Cardiac function assessment	Normal cardiac function
Heart failure with preserved ejection fraction	Cardiac function assessment	Heart failure with preserved ejection fraction
Heart failure with reduced ejection fraction	Cardiac function assessment	Heart failure with reduced ejection fraction

Primary Outcome Measures

Name	Time	Method
Mortality	2 year	Mortality of patients

Trial Locations

Locations (2)

Frydek Mistek Hospital; 🇨🇿 Frýdek-Místek, Czechia

University Hospital Olomou; 🇨🇿 Olomouc, Czechia